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Ebola virus (EBOV), a member of the filovirus family, is an enveloped negative-sense RNA virus that causes lethal infections 
in humans and primates. Recently, more than 1000 people have been killed by the Ebola virus disease in Africa, yet no specific 
treatment or diagnostic tests for EBOV are available. In this study, we identified two putative viral microRNA precursors 
(pre-miRNAs) and three putative mature microRNAs (miRNAs) derived from the EBOV genome. The production of the 
EBOV miRNAs was further validated in HEK293T cells transfected with a pcDNA6.2-GW/EmGFP-EBOV-pre-miRNA plas-
mid, indicating that EBOV miRNAs can be produced through the cellular miRNA processing machinery. We also predicted 
the potential target genes of these EBOV miRNAs and their possible biological functions. Overall, this study reports for the 
first time that EBOV may produce miRNAs, which could serve as non-invasive biomarkers for the diagnosis and prognosis of 
EBOV infection and as therapeutic targets for Ebola viral infection treatment. 
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The Ebola virus (EBOV), a member of the filovirus family, 
is an enveloped negative-sense RNA virus that causes se-
vere and frequently lethal infections in humans and primates 
[1]. Recently, more than 1000 people have been killed by 
Ebola virus disease in Africa, and many other areas (e.g., 
Benin, America, and Canada) have also reported suspected 
cases [2,3]. The disease has a high risk of death, killing be-
tween 50% and 90% of those infected with the virus [4]. 
However, no specific treatment or diagnostic tests for 
EBOV are currently available [5]. 
As a class of small non-coding RNAs ranging from 19 to 
24 nucleotides (nt) in length, microRNAs (miRNAs) regu-
late the expression of target genes at the posttranscriptional 
level [68]. miRNAs are not only found in numerous eu-
karyotes but are also employed by viruses to regulate the 
expression of their own genes, the host’s genes, or both 
[911]. Most viral miRNAs have been identified from vi-
rus-infected cells using traditional cloning strategies 
[1215], although some have been identified following 
computational prediction and hybridization analysis 
[1517]. Currently, the miRBase database lists 30,424 
miRNAs [18,19], of which 501 are viral miRNAs. It is 
worth noting that the majority of known viral miRNAs are 
encoded by DNA viruses. Indeed, DNA-virus-encoded 
miRNAs are generally accepted, as viruses with DNA ge-
nomes replicate in the nucleus and thus have access to the 
cellular miRNA processing machinery; in contrast, RNA 
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viruses replicate in the cytoplasm and, therefore, are not 
expected to encode miRNAs [911]. It has also been spec-
ulated that RNA viruses do not generate miRNAs to avoid 
the adverse effects caused by the miRNA processing ma-
chinery [11]. Therefore, naturally occurring miRNAs de-
rived from RNA viruses have not been widely acknowl-
edged. Despite the theoretical barriers preventing RNA vi-
ruses from encoding miRNAs, recent studies have con-
firmed that laboratory-engineered RNA viruses, including 
the influenza virus, sindbis virus, and vesicular stomatitis 
virus (VSV), are capable of expressing miRNA-like small 
RNAs [2025]. Furthermore, a few retroviruses, including 
the human immunodeficiency virus (HIV) [26,27], bovine 
leukemia virus (BLV) [28,29] and three cytoplasmic RNA 
viruses, the West Nile virus (WNV) [30], Dengue virus 
(DENV) [31] and hepatitis A virus (HAV) [20], were found 
to encode miRNAs, although the underlying mechanisms 
remain unclear. 
In this study, we hypothesized that the genome of Ebola 
virus could produce miRNAs using the cellular miRNA 
processing machinery. To validate this, we used a strategy 
that combined computational prediction and experimental 
validation to search for putative EBOV miRNAs. This study 
provides evidence to support the hypothesis that EBOV can 
encode functional miRNAs through the cellular miRNA 
processing machinery. In addition, our findings provide a 
basis for further assessing the roles of the EBOV miRNAs 
during viral infection and virus-host interactions.  
1  Materials and methods 
1.1  Cells, plasmids and reagents 
HEK293T cells were purchased from Thermo Scientific 
(Cat No. HCL4517) and grown in Dulbecco’s modified 
Eagle’s medium (DMEM) (high glucose formulation, Gibco 
Life Technologies, Grand Island, NY, USA) supplemented 
with 10% fetal calf serum (Gibco Life Technologies, Grand 
Island, NY, USA) at 37°C in a humid environment contain-
ing 5% CO2. The eukaryotic expression plasmids, 
pcDNA6.2-GW/EmGFP-EBOV-pre-miR-1 and pcDNA6.2- 
GW/EmGFP-EBOV-pre-miR-2, and the wild-type and mu-
tant sensor plasmids (pmirGLO-EBOV-miRNA-wild and 
pmirGLO-EBOV-miRNA-mut) were purchased from 
GenePharma (Shanghai, China). All constructs generated 
were confirmed by sequencing using universal primers 
(BGI, Guangzhou, China). The mouse monoclonal an-
ti-Dicer1 antibody 5D12.2 (1:5000 dilution; mouse mono-
clonal; Millipore Corporation, Billerica, MA, USA), a rab-
bit anti-GAPDH polyclonal antibody (G-9) (sc-365062; 
1:2000 dilution; rabbit polyclonal; Santa Cruz, CA, USA), 
and the appropriate HRP-conjugated anti-mouse and an-
ti-rabbit secondary antibodies (1:10,000 dilution; Pro-
teintech Group, Inc. Chicago, IL, USA) were used for im-
munoblotting. 
1.2  Bioinformatics prediction of the miRNAs 
A flowchart describing the computational prediction of the 
putative miRNAs is shown in Figure 1. Briefly, the viral 
genome was scanned for stem-loop structures of miRNA 
precursor (pre-miRNA) using VMir [32], a computational 
analyzer program for the prediction of putative pre-miRNAs. 
The complete genome sequences of different EBOV strains, 
the Sudan ebolavirus strain Gulu and the Zaire ebolavirus 
strain Mayinga-Volchkov (GenBank accession No. 
NC_006432 and NC_002549), were used. VMir predictions 
were carried out using the default parameters. The putative 
pre-miRNAs that satisfied the filter parameters of a VMir 
score 150 and a window count 35 were selected for fur-
ther assessment. Then, the source code of MiPred [33] was 
used to distinguish real and pseudo miRNA precursors from 
the obtained sequences with a prediction confidence equal 
to or greater than 70%. Subsequently, mature miRNA se-
quences were predicted from the pre-miRNA stem-loops. 
To extend the prediction coverage of the mature miRNAs, 
we used two strategies: the MatureBayes tool [34] and the 
Bayes-SVM-MiRNA web server v1.0 [35]. The default 
conditions were used for the MatureBayes tool. The folding 
energy was set at 15 kcal mol1 when using the 
Bayes-SVM-MiRNA web server v1.0; other filter parame-
ters were set to the default values. 
1.3  RNA interference (RNAi) of the Dicer gene 
The following siRNA sequence targeting the human Dicer 
cDNA was designed and synthesized by GenePharma 
(Shanghai, China): 5′-UAAAGUAGCUGGAAUGAUG-3′. 
A scrambled siRNA was included as a negative control. The 
Dicer siRNA was transfected into HEK293T cells using  
 
 
Figure 1  Flowchart of EBOV-encoded miRNA prediction. The VMir 
analyzer program was used to predict the putative EBOV genome-encoded 
pre-miRNA stem-loop structures, MiPred algorithm was used to identify 
genuine pre-miRNAs, and the MatureBayes tool and the Bayes-SVM- 
MiRNA web server v1.0 were used to predict the mature miRNA sequences. 
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Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. Total RNA and 
protein were isolated 24 h post transfection. The Dicer 
mRNA and protein expression levels were assessed by 
quantitative RT-PCR and Western blotting. 
1.4  RNA isolation and quantitative RT-PCR 
Total RNA was extracted from the cultured cells and human 
tissues using the TRIzol Reagent (Invitrogen) according to 
the manufacturer’s instructions. Assays to quantify the viral 
miRNAs were performed using miRNA probes (Gene- 
Pharma, Shanghai, China) according to the manufacturer’s 
instructions. Briefly, 1 µg of total RNA was reverse-   
transcribed to cDNA using the AMV reverse transcriptase 
(TaKaRa, Dalian, China) and a stem-loop RT primer 
(GenePharma). The reaction conditions were as follows: 
16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. Re-
al-time PCR was performed using a GenePharma PCR kit 
on an Applied Biosystems 7900 Sequence Detection System 
(Applied Biosystems). The reactions were incubated in a 
96-well optical plate at 95°C for 10 min, followed by 40 
cycles of 95°C for 15 s and 60°C for 1 min. All of the reac-
tions were run in triplicate. After the reaction, the cycle 
threshold (CT) data were determined using fixed threshold 
settings, and the mean CT of the triplicate PCRs was deter-
mined. A comparative CT method was used to compare each 
condition to the controls. The relative levels of the miRNAs 
in the cells and tissues were normalized to U6. The amount 
of miRNA relative to the internal control U6 was calculated 
using the 2△△CT equation, in which CT=(CT miRNA
CT U6)target(CT miRNACT U6)control. 
To quantify the Dicer mRNA, 1 µg of total RNA was re-
verse-transcribed to cDNA using oligo dT and Thermoscript 
(TaKaRa); reaction conditions were as follows: 42°C for  
60 min and 70°C for 10 min. Next, real-time PCR was per-
formed using the RT product, SYBER Green Dye (Invitro-
gen), and specific primers for Dicer and GAPDH. The se-
quences of the primers were as follows: Dicer (sense): 5′- 
TGCTATGTCGCCTTGAATGTT-3′; Dicer (antisense): 
5′-AATTTCTCGATAGGGGTGGTCTA-3′; GAPDH (sen- 
se): 5′-GATATTGTTGCCATCAATGAC-3′; and GAPDH 
(antisense): 5′-TTGATTTTGGAGGGATCTCG-3′. The 
reactions were incubated at 95°C for 5 min, followed by 40 
cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. 
After the reactions were complete, the CT values were de-
termined by setting a fixed threshold. The relative amount 
of Dicer mRNA was normalized to GAPDH. 
1.5  Western blot analysis 
The total protein in the cell extracts was quantified using the 
BCA protein assay Kit (Pierce, Rockford, IL, USA) ac-
cording to manufacturer’s instructions. Thirty micrograms 
of total protein were resolved on 8% SDS-PAGE gels and 
transferred onto PVDF membranes (Millipore, Billerica, 
MA, USA), followed by blocking with 5% non-fat milk at 
room temperature for 2 h. Membranes were probed with the 
specific primary antibodies overnight at 4°C, followed by 
incubation with the appropriate (anti-mouse or anti-rabbit) 
HRP-conjugated secondary antibodies at room temperature 
for 1 h. Protein signals were visualized by ECL chemilumi-
nescence using the Immobilon Western HRP Substrate 
(Millipore Corporation, Billerica, MA, USA) according to 
the manufacturer’s protocol. 
1.6  Luciferase reporter assay 
A dual luciferase reporter assay using the sensor plasmids 
(pmirGLO-EBOV-miRNA-wild and pmirGLO-EBOV- 
miRNA-mut) was performed in HEK293T cells. Briefly, 
HEK293T cells were seeded at approximately 1×106 cells 
per well in a 24-well plate one day prior to transfection. The 
next day, 200 ng of either the pmirGLO-EBOV-miRNA- 
wild or the pmirGLO-EBOV-miRNA-mut plasmid were 
co-transfected with 20 pmol of chemically synthesized 
miRNA mimics (GenePharma, Shanghai, China) or 200 ng 
of pcDNA6.2-GW/EmGFP-EBOV-pre-miRNA plasmid 
into the HEK293T cells with Lipofectamine 2000 (Invitro-
gen). The firefly and Renilla luciferase activities were eval-
uated simultaneously 48 h post-transfection using the Du-
al-Glo™ Luciferase Assay System (Promega, Madison, WI, 
USA) according to the manufacturer’s protocol. Relative 
luciferase activity was expressed as the ratio of firefly to 
Renilla luciferase activity. The transfections were per-
formed independently in triplicate. 
1.7  Statistical analysis 
Data were presented as mean±SE. Values from three inde-
pendent experiments were analyzed by two-tailed Student’s 
t-tests. P<0.05 was considered to be statistically significant. 
2  Results 
2.1  Prediction of pre-miRNAs and mature miRNAs 
encoded by the EBOV genome 
Computational prediction represents an effective strategy to 
identify novel miRNAs, which can be further validated by 
experimental approaches. We followed this strategy and 
investigated whether the EBOV genome contained se-
quences that can fold into the stem-loop structures of 
pre-miRNA. Two strains of EBOV, Sudan ebolavirus (Su-
dan ebolavirus strain Gulu, GenBank accession No. 
NC_006432) and Zaire ebolavirus (Zaire ebolavirus strain 
Mayinga-Volchkov, GenBank accession No. NC_002549), 
were analyzed using the VMir analyzer program [32], and 
seven sequences with potential stem-loop structures were 
found (Figure 1). Then, the MiPred algorithm was used to 
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narrow down the seven candidates using characteristics of 
genuine pre-miRNAs. Two putative pre-miRNAs, named 
EBOV-pre-miR-1 and EBOV-pre-miR-2, were retained 
(Table 1). The VMir analyzer program further showed that 
the two selected pre-miRNAs were conserved among dif- 
ferent EBOV strains (GenBank accession No. NC_006432,  
AF499101, AF272001, AY142960, NC_002549, AY- 
354458, EU224440, and EU338380), with VMir scores 
200 and window counts 50 (Figure 2A). The RNAFold 
algorithm was then used to show that EBOV-pre-miR-1 and 
EBOV-pre-miR-2 had the typical stem-loop structure of 
pre-miRNAs (Figure 2B). The mature miRNAs produced by 
the two pre-miRNAs were predicted using the MatureBayes 
tool [34] and the Bayes-SVM-MiRNA web server v1.0 [35]. 
Both algorithms identified three putative mature miRNAs 
that were 22 nt in length, namely EBOV-miR-1-5p, 
EBOV-miR-1-3p and EBOV-miR-2-3p (Table 2). Overall, 
we identified two putative pre-miRNAs and three putative 
mature miRNAs from the genome of EBOV using compu-
tational approaches. 
2.2  Detection of EBOV miRNAs in HEK293T cells 
transfected with the pcDNA6.2-GW/EmGFP-EBOV- 
pre-miRNA plasmid 
Next, we employed a plasmid-derived miRNA expression 
system to determine whether the EBOV miRNA can be 
processed by the cellular miRNA processing machinery. 
EBOV-pre-miR-1 and EBOV-pre-miR-2 were cloned into 
the mammalian expression plasmid pcDNA6.2-GW/ 
EmGFP to generate the recombinant pcDNA6.2-GW/ 
EmGFP-EBOV-pre-miRNA plasmid, which was then 
transfected into HEK293T cells (Figure 3A). A plasmid that 
expressed scrambled small RNA was also transfected into 
HEK293T cells as the negative control. A strong fluorescent 
signal was observed under fluorescence microscopy in both 
transfected cell groups (Figure 3B). RT-PCR analysis re- 
vealed that the EBOV miRNAs were expressed as an ap-
parent band of 100 bp in HEK293T cells transfected with  
the pcDNA6.2-GW/EmGFP-EBOV-pre-miRNA (Figure  
3C). In contrast, no bands were detected in cells transfected 
with the negative control plasmid. Sequence analysis of the 
PCR product indicated that the PCR-amplified sequence 
was identical to the EBOV miRNAs.  
To determine whether the EBOV miRNAs were gener-
ated using the cellular miRNA processing pathway, we si-
lenced Dicer using an RNAi approach in HEK293T cells. 
Efficient knockdown of Dicer was confirmed by qRT-PCR 
and Western blotting (Supplementary Figure S1). Dicer- 
deficient and wild-type HEK293T cells were transfected 
with the pcDNA6.2-GW/EmGFP-EBOV-pre-miRNA plas-
mid, and qRT-PCR analysis was performed to measure the 
levels of the EBOV miRNAs. A dramatic reduction in the 
EBOV miRNA levels was found in Dicer-deficient cells 
compared with wild-type cells (Figure 3D), suggesting that 
the generation of EBOV miRNA is dependent on the Dicer 
processing pathway.  
2.3  EBOV-encoded miRNAs are biologically functional  
miRNAs usually negatively regulate gene expression by 
binding to the 3′-untranslated region (3′-UTR) of target 
mRNA molecules [30,36]. To determine whether the EBOV 
miRNAs are functionally active, we predicted the target 
genes of EBOV miRNAs using Targetscan [37] and 
RNAhydrid [38] (Supplementary Table S1). According to 
GO analysis, the EBOV miRNAs have the ability to inhibit 
human genes involved in T and B cell activation, nature 
killer cell-mediated cytotoxicity, adherens junction, and 
apoptosis. These results strongly imply that immune escape, 
endothelial cell rupture and tissue dissolution during EBOV 
infection is due to the action of the EBOV miRNAs.  
Subsequently, a dual-luciferase reporter assay using ei-
ther the pmirGLO-EBOV-miRNA-wild or the pmirGLO- 
EBOV-miRNA-mut plasmid was performed in HEK293T  
Table 1  The predicted pre-miRNAs in EBOV 
Pre-miRNA Sequence (5′–3′) Strand  Start 
position 
Length 
Minimum of free 












+ 14252 89 19.8 
Table 2  The predicted mature miRNAs in EBOV 
Mature miRNA Sequence (5′3′) Length 
EBV-miR-1-5p AAAAAGUCCAUAAUGCUGGGGA 22 
EBV-miR-1-3p GCCACCAUAGGACUUUUUCAAU 22 
EBV-miR-2-3p UUAUCCUUCUUGAAUCCUGAGA 22 
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Figure 2  VMir prediction of EBOV-encoded pre-miRNAs. A, The two candidate pre-miRNAs with high scores are colored red (EBOV-pre-miR-1) and 
blue (EBOV-pre-miR-2). The VMir analyzer program was used to predict candidate pre-miRNAs in the EBOV genome with a cutoff score of 150 and a 
cutoff window count of 35. The y-axis represents the VMir scores, while the x-axis indicates the nucleotide position. B, Secondary structures of the predicted 
candidate EBOV pre-miRNAs. Mature miRNAs in the 5′ and 3′ strands are shown in red and blue, respectively. 
A 
B 
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Figure 3  Detection of EBOV miRNAs from plasmid-expressed precursor miRNA (pre-miRNA). A, Construction of the EBOV miRNA expression plas-
mid. Each EBOV pre-miRNA sequence was cloned into the pcDNA6.2-GW/EmGFP plasmid. A plasmid containing scrambled sequences was used as a 
negative control. B, HEK293T cells were transfected with the miRNA expression plasmids, and strong green fluorescence was observed in both transfected 
cell lines (100×). C, Detection of mature miRNA expression. Small RNAs were harvested at 24 h post-transfection, and mature miRNAs were detected by 
stem-loop RT-PCR in both transfected cell lines. D, Plasmid-expressed miRNA levels were reduced in Dicer-deficient HEK293T cells compared to 
wild-type negative control cells. Significant differences in the expression levels were determined by Student’s t-test (*, P<0.05; **, P<0.01; ***, P<0.001). 
cells (Figure 4A). First, we tested the effect of synthetic 
EBOV miRNA mimics on the expression of the luciferase 
gene containing artificial targets of EBOV miRNA. The 
efficient overexpression of EBOV miRNAs in HEK293T 
cells is shown in Supplementary Figure S2A. Luciferase 
activity was significantly reduced when cells were co- 
transfected with the EBOV miRNA mimics and the pmir-
GLO-EBOV-miRNA-wild plasmid compared to those 
co-transfected with the mimics and mutant plasmid (Figure 
4B). Second, we co-transfected the pcDNA6.2-GW/ 
EmGFP-EBOV-pre-miRNA plasmid with the pmirGLO- 
EBOV-miRNA-wild/mut plasmid into HEK293T cells. The 
efficient overexpression of the EBOV miRNAs in 
HEK293T cells is shown in Supplementary Figure S2B. A 
dramatic decrease in luciferase activity was observed in the 
cells transfected with the pcDNA6.2-GW/EmGFP-EBOV- 
pre-miRNA plasmid (Figure 4C). These data suggest that 
the EBOV miRNAs are capable of silencing the expression 
of the luciferase gene containing artificial targets of the 
EBOV miRNAs. Overall, these results suggest that the 
EBOV-encoded miRNAs are functionally active. 
3  Discussion 
According to the criteria proposed by Ambros et al. [39], 
small RNAs can be defined as genuine miRNAs if they ful-
fill a combination of structural and expression criteria. Here, 
putative EBOV miRNAs were defined as bona fide mi- 
RNAs in that they fulfilled these annotation criteria. In ad-
dition, they were identified as genuine miRNAs based on 
the miRNA biogenesis pathway. Similar to previously identi-
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Figure 4  EBOV-encoded miRNAs are biologically functional. A, Construction of the wild and mut plasmids. The wild-type construct was created by 
inserting two tandem repeats of artificial target sites that were perfectly complementary to the miRNA sequences into the 3′ UTR of the luciferase gene in the 
sensor plasmid, and the mutant construct was created by inserting two tandem repeats containing mutated nucleotides in the artificial target sites. B, Silenc-
ing activity of the exogenous viral miRNAs in HEK293T cells transfected with viral miRNA mimics. C, Silencing activity of the EBOV miRNAs in cells 
transfected with the sensor plasmid and with the pcDNA6.2-GW/EmGFP-EBOV-pre-miRNA plasmid. Luciferase activity was assessed 48 h after transfec-
tion. For all treatments, relative luciferase activity was expressed as ratio of firefly to Renilla luciferase activity. Error bars indicate the standard deviation 
obtained from three replicates, and significant differences are indicated with * for P<0.05, ** for P<0.01 and *** for P<0.001. 
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fied viral miRNAs from WNV [24], DENV [31], and HAV 
[20], silencing Dicer led to a significant decline in the 
EBOV miRNA levels. These findings suggest that a cyto-
plasmic RNA virus can utilize the cellular miRNA pro-
cessing machinery to produce its own miRNAs.  
Although several novel miRNAs have been experimen-
tally identified in the WNV [30], DENV [31] and HAV [20] 
genomes, it remains controversial whether a virus with an 
RNA genome that replicates in the cytoplasm can naturally 
encode functional miRNAs or miRNA-like small RNAs. 
Computational prediction followed by experimental valida-
tion constitutes an effective and fast strategy for the discov-
ery of novel miRNAs, and several studies have previously 
employed this strategy to identify viral miRNAs in numer-
ous viruses [20,4042]. In this study, two miRNA precur-
sors, EBOV-pre-miR-1 and EBOV-pre-miR-2, were identi-
fied using the same strategy and were shown to be com-
pletely conserved among different EBOV strains. The find-
ings provide new evidence that cytoplasmic RNA viruses 
can encode functional miRNAs. 
Until now, there has been no specific diagnostic test for 
EBOV. Recently, we and other groups have demonstrated 
that miRNAs circulate in a highly stable, cell-free form in 
body fluids and that circulating miRNAs can be used as 
non-invasive biomarkers for molecular diagnostics and 
prognostics. The identification of EBOV miRNAs suggests 
opportunities for the development of circulating EBOV 
miRNAs as non-invasive biomarkers for the molecular di-
agnosis of EBOV infection at an early stage.  
Further investigations will be needed to determine the 
mechanisms by which the EBOV genome encodes miR-
NA-like small RNAs and the potential biological function 
of the viral miRNAs during infection and host-virus interac-
tions. Nevertheless, the preliminary prediction that EBOV 
hosts express EBOV miRNA target genes provides some 
clues for better understanding the regulatory roles of EBOV 
miRNAs. Ebola causes highly lethal hemorrhagic fever in 
humans, with no licensed countermeasures [43]. Its viru-
lence can be attributed to several immunoevasion mecha-
nisms: the early inhibition of innate immunity initiated by 
the downregulation of type I interferon, epitope masking, 
and subversion of the adaptive humoral immunity by se-
creting a truncated form of the viral glycoprotein [43]. De-
ficiencies in both specific and non-specific antiviral re-
sponses result in unrestricted viral replication and dissemi-
nation in the host, typically causing death within 10 days 
after the appearance of symptoms [43]. The results of cellu-
lar target prediction analysis indicate that EBOV miRNAs 
could regulate the expression of host genes involved in vi-
rus-cell interaction, immune escape, and cell apoptosis, 
which may explain how the Ebola virus can mass duplicate 
without detection by the host immune system and cause 
severe hemorrhagic fever symptoms. Interestingly, we 
found that the Reston EBOV strain did not encode these 
miRNAs, in contrast to the Sudan EBOV and Zaire EBOV 
strains. Unlike the Reston EBOV strain, the Sudan EBOV 
and Zaire EBOV strains have high pathogenicity and mor-
tality rates in humans; the miRNAs encoded by EBOV may 
explain these differences, at least in part.  
In summary, we have identified two putative viral 
pre-miRNAs and three mature miRNAs derived from 
EBOV and showed that the EBOV miRNAs can be gener-
ated using the cellular miRNA processing machinery. The 
EBOV miRNAs may have potential as non-invasive bio- 
markers for the molecular diagnosis and prognosis of 
EBOV infection and as therapeutic targets for the treatment 
of EBOV disease. 
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Figure S1  Knockdown of Dicer reduces the expression of EBOV-encoded miRNAs. A, Dicer protein was knocked down by RNAi and confirmed by 
Western blot. GAPDH was used as a loading control. B, Dicer mRNA was knocked down by RNAi and confirmed by qRT-PCR. Significant differences in 
expression levels were detected by Student’s t-test (*, P<0.05; **, P<0.01; ***, P<0.001). 
Figure S2  The EBOV-encoded miRNAs levels in HEK293T cells. A, Quantitative RT-PCR analysis of EBOV-encoded miRNAs levels in HEK293T cells 
treated with mimic NC, or EBOV-miRNAs mimics. B, Quantitative RT-PCR analysis of EBOV-encoded miRNAs levels in HEK293T cells treated with 
pcDNA6.2-GW/EmGFP, or pcDNA6.2-GW/EmGFP-EBOV-pre-miRNAs. Significant differences in expression levels were detected by Student’s t-test (*, 
P<0.05; **, P<0.01; ***, P<0.001). 
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